Effect of plozasiran on lipoprotein particles by NMR | JACC | ACC.25

In this insightful discussion, Christie Ballantyne, MD, FACC shares research on targeting APOC-III with Plozasiran to manage hypertriglyceridemia. He and JACC Associate Editor Marc P. Bonaca, MD, FACC discuss the impact on lipoprotein particle size, LDL composition, and potential cardiovascular benefits. Don't miss this deep dive into the future of lipid management and cardiovascular risk reduction – listen now and read the study in JACC: https://www.jacc.org/doi/10.1016/j.jacc.2025.03.496 #jaccjournals #jacc #acc25